Patient C.M. presented platelet function defects symptomatic of Glanzmann's thrombasthenia. However, analysis of surface-labeled platelets by SDS-polyacrylamide gel electrophoresis revealed the usual presence of the major glycoproteins, including GP IIb and GP IIIa. Platelet fibrinogen was not detected. Analysis of Triton X-100 extracts of Ca2+-washed C.M. platelets by crossed immunoelectrophoresis (CIE) showed normal amounts of GP IIb-IIIa complexes. However, when samples were electrophoresed through an agarose gel containing 125I-fibrinogen, the usual binding of fibrinogen to GP IIb-IIIa did not occur. Furthermore, the GP IIb-IIIa complexes showed an increased sensitivity to dissociation with EDTA, either after Triton X-100 solubilization or in the intact platelet membrane. For example, after incubation with EDTA at room temperature, the patient's platelets bound little of the monoclonal antibodies AP-2 or T10 (anti-GP IIb-IIIa complex) although normally binding Tab (anti-GP IIb). Patient C.M. appears to represent a subgroup of thrombasthenia where platelets contain unstable GP IIb-IIIa complexes unable to support fibrinogen binding.
Introduction
Glanzmann's thrombasthenia is a rare blood disorder characterized;in vitro, by the absence ofplatelet aggregation in response to ADP and other physiologic agonists (1, 2) . Numerous studies suggest that the hemorrhagic tendency arises from the inability ofthe platelets to adhere one with another after activation, with the result that thrombus formation does not occur (reviewed in reference 3). In most patients, platelets are also unable to support clot retraction.
In 1974, Nurden and Caen described glycoprotein (GP)I abnormalities when membrane fractions isolated from the platelets ofthree patients were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (4) . It is now generally recognized that A preliminary report of part ofthis study has appeared in abstract form (1983, Thromb. Haemostasis, 50:216a) . Address correspondence to Dr. Nurden, U-150 INSERM, Hopital Lariboisiere, 6 rue Guy Patin, 75475 Paris Cedex 10, France.
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1. Abbreviations used in this paper: ACD, acid citrate dextrose; CB-R, Coomassie Blue R-250; CIE, crossed immunoelectrophoresis; GP, glycoprotein; PRP, platelet-rich plasma.
a major lesion of thrombasthenic platelets is the absence, or severe reduction in concentration, ofmembrane GP Ilb and GP IIIa (3, (5) (6) (7) (8) . Platelet fibrinogen is also often absent or decreased. The finding that fibrinogen binding to ADP-stimulated thrombasthenic platelets was defective (9) (10) (11) (12) was initial evidence that the missing GPs might constitute part of the platelet fibrinogen receptor. When solubilized from platelet membranes with nonionic detergent, GP fib and GP lila are present as divalent cationmediated heterodimer complexes (13, 14) . A number of monoclonal antibodies have been prepared that recognize determinants on GP Ilb-lIla (15) ; with some, the binding sites are lost after divalent cation chelation and GP fib-Ha dissociation. Two such antibodies are AP-2 (16) and TIO (17) . An extensive binding of these antibodies to unstimulated platelets implies that IIb-IIIa heterodimers are a normal constituent of the circulating platelet membrane. Thus, thrombasthenia may be seen essentially as a disorder of the GP ib-IIIa complexes.
Functional heterogeneity in Glanzmann's thrombasthenia was first noted by Caen (2) who proposed two patient subgroups, with the rare type II patients differing from those with type I disease in that their platelets were able to support a modified clot retraction and possessed appreciable amounts of platelet fibrinogen. Subsequent studies using crossed immunoelectrophoresis (CIE) revealed that platelets ofthe type I patients lacked, or merely contained trace amounts of GP IIb-IIIa complexes (6, 8, 18, 19) , whereas platelets ofpatients in the type II subgroup contained more ofthese GPs (6, 19) . Recent preliminary reports have also described patients with at least 50% of the normal content ofGP IIb and GP HiUa in their platelets, while exhibiting all of the clinical and platelet function abnormalities typical of Glanzmann's thrombasthenia (20-23). We now describe studies on one such patient whose platelets contain GP Ilb-I11a complexes that are unusually susceptible to dissociation by EDTA and that are unable to support fibrinogen binding. It is proposed that the patient represents a new variant or subgroup of the disease.
Methods
Subjects. The patient (C.M.) was referred to us as a typical case of type I Glanzmann's thrombasthenia (1, 2) . A white female now 24 yr old, she has experienced bleeding since birth. The first major event occurred after a fall when she was 2 yr old. Bleeding episodes have since continued at irregular intervals, and have featured severe epistaxis, spontaneous gingival bleeding, and hemorrhagia. Although she has received blood transfusions on several occasions, tests for anti-platelet antibodies have always been negative. The patient has been examined by us on four occasions over 5 yr. Her platelet count was normal, 2 X 101 platelets/ ml at the last time of study. White cell and red cell counts were also normal. The Duke bleeding time was prolonged (> 10 min). Ristocetin-tests showed no plasma or coagulation factor abnormalities. There is no family history ofa bleeding disorder and platelet function of both parents was normal. Consanguinity has been excluded. Control donors were adult volunteers from hospital staff.
Platelet function testing. Platelet aggregation in citrated platelet-rich plasma (PRP) was studied in a Payton platelet aggregometer (Payton Scientific Inc., Buffalo, NY) using standard procedures. Washed platelets were prepared from acid citrate dextrose (ACD) anticoagulated blood using the buffer systems of Patscheke (24) as adapted by Legrand et al.
(25). The platelets were finally resuspended in a modified Tyrode buffer (Tyrode-Ca2") which consisted of 137 mM NaCl, 3 mM KCl, 12 mM NaHCO3, 0.3 mM NaH2PO4 2H20, 2 mM CaCI2, I mM MgCI2, 5.5 mM glucose, 5 mM Hepes (pH 7.4), and 0.35% wt/vol bovine serum albumin (BSA). On occasion, platelets were prelabeled by incubating the PRP with 0.6 MM ['4C]serotonin (40 mCi/mmol; Radiochemical Centre, Amersham, England) for 30 min at 370C. Aggregation was studied at 370C with constant stirring (1,100 rpm) using samples adjusted to 3 X 108 platelets/ml. Stimuli used included 1-10 IM ADP (disodium salt; Sigma Chemical Co., St. Louis, MO) in the presence of200 Mg/ml dialysed human fibrinogen (Kabi Diagnostics, Stockholm, Sweden), 12.5-50.0 pg/ml polymerized type I calfskin collagen (from Dr. Y. Legrand, H6pital
Saint-Louis, Paris) and 0.05-1.00 U/ml human a-thrombin (from Dr.
M. C. Guillin, Faculte Bichat, Paris). The purity of the collagen preparation has been previously assessed (25) while the purified human athrombin had an activity of 3,000 NIH U/ml protein. Samples were taken after 3 min for ['4C]serotonin release (25). Clot retraction was studied by incubating I ml of citrated PRP, diluted twice with 0.15 M NaCl, with 0.5 U thrombin in glass tubes at 37°C for I h.
Fibrinogen binding to stimulated platelets. Fibrinogen binding to ADP-or collagen-stimulated platelets was studied as previously described by us (25, 26 Analysis ofplatelet proteins and GPs by one-dimensional SDS-PAGE and two-dimensional acrylamide gel electrophoresis. repeated with platelets labeled with 3H incorporated into the surface exposed carbohydrate chains of the membrane glycoproteins (see Methods). The labeling intensities of the major glycoproteins of control and C.M. platelets were compared by densitometric scanning after fluorography. The patterns were indistinguishable, and were similar to those previously described by us for normals (27). In particular, the analysis after disulfide reduction showed the usual presence of both the a-and ,8-subunits of GP HIb in C.M. platelets. In a further attempt to uncover structural defects in GP lIb and/or GP Illa, detergent-soluble extracts of '251I-labeled C.M. platelets were analyzed by high resolution two-dimensional gel electrophoresis incorporating isoelectric focusing in the first dimension. Fig. 4 reveals a normal migration and isoelectric point for GP HIb and GP IIIa of C.M. platelets.
CIE. Initial investigations were performed using platelets washed in Tris-EDTA as in our previous studies using this technique (6, 8, 13, 19) and in the SDS-PAGE experiments described above. Fig. 5 compares the autoradiographs obtained after the analysis ofTriton X-100 extracts of '251-labeled C.M. and control platelets. A striking decrease in the size of the GP lIb-Ila precipitate was a marked feature of the C.M. platelet pattern. Additional precipitates in positions similar to those previously identified as containing dissociated GP Ilb and GP I11a (13) were clearly apparent. CB-R staining (not shown) revealed the decreased content of GP IIb-IIIa complexes but did not permit the detection of the additional precipitates, which were in part masked by others in this region of the gel. CB-R staining, however, confirmed the decreased fibrinogen content of C.M. platelets previously illustrated in Fig. 3 . Performing the detergent solubilization in the presence ofa cocktail ofprotease inhibitors (see Methods) did not restore the normal GP IIb-IIIa precipitate to the C.M. platelet pattern. Analysis ofthe Triton X-100-soluble Figure 4 . Two-dimensional electrophoresis of the '251-labeled surface glycoproteins of C.M. and normal human platelets. SDS-soluble extracts (200 lg protein) of radiolabeled platelets were made 9 M with urea and Triton X-100 added to give a 4:1 ratio with respect to the SDS. After first-dimension separation by isoelectric focusing, the gels were incubated with 2% SDS and 5% 2-mercaptoethanol during 1 h at room temperature. Second-dimension separation of the reduced proteins was by SDS-PAGE using 7 Further experiments were performed to confirm the identification of the precipitates highlighted on Fig. 5 . This confirmation was achieved using Triton X-100 extracts of unlabeled platelets and '25I-labeled monoclonal antibodies in the intermediate gel. TlO, which is specific for GP IIb-HIa complexes ( 17) , labeled only the residual precipitate present in the IIb-IIIa position on the C.M. platelet pattern (Fig. 6) . AP-2, a different antibody with a similar specificity (16), behaved identically (not illustrated). In contrast, Tab, which recognizes dissociated GP Ilb (17), labeled both the residual GP IIb-IIIa complexes in increased amounts and the precipitate in the position ofdissociated GP I1b.
The above results suggested that either circulating C.M. platelets contained appreciable amounts of dissociated GP Ilb and GP Illa, or that complex dissociation was occurring during the experimental procedures leading to the CIE. Platelets were therefore isolated in the presence of divalent cations and Triton X-100 extracts analyzed by CIE. Fig. 7 shows that GP IIb-IIIa complexes were normally present in C.M. platelets isolated in this way. The additional precipitate located by Tab in Fig. 6 was no longer present. The GP Ilb-IIIa complexes were also normally observed by CB-R staining.
The following experiments were performed to see if the GP IIb-IIIa complexes of C.M. platelets were more sensitive to divalent cation chelation in solution. Previous studies have shown that at 4VC and pH 8.7, EDTA induces a slow dissociation of GP IIb-IIIa complexes in Triton X-100 extracts of normal platelets (30, 31) . Other studies showed an approximate 80% dissociation of GP IIb-IIIa ofC.M. platelets using 1 mM EDTA for 1 h under these conditions, while no dissociation was observed with a mixture of 2 mM EDTA and 5 mM CaCl2.
Monoclonal antibody binding to intact platelets. These studies were designed to illustrate whether EDTA-induced modifications of GP IIb-IIIa actually occurred in the surface membrane of C.M. platelets. Binding studies were performed using '25I-labeled T10, AP-2, or Tab and platelets that had been washed in the presence of divalent cations but were incubated in Tyrode-Ca2+ or Tyrode-EDTA for 30 min at room temperature before the addition of the antibody. The number of binding sites expressed by C.M. platelets for each antibody was calculated and Table II gives the results. In our binding assay, AP-2 binds to 39,400±5,800 sites on control platelets and the number is unchanged after divalent cation chelation (see Table I and reference 31). As Table II shows, the binding of AP-2 to C.M. platelets in the presence of Ca2+ was in the normal range, yet after divalent cation chelation the binding was reduced to < 10% ofthis level. TO0 behaved similarly to AP-2, with few binding sites expressed on C.M. platelets after EDTA treatment. In contrast, binding of Tab to C.M. platelets was identical with or without divalent cation chelation, showing that GP Ilb remained exposed at the platelet surface in the presence ofEDTA. The number ofbinding sites for T10 and Tab on control platelets under our conditions did not differ from those reported in Table I .
Binding of "I-fibrinogen to GP Jib-IIIa complexes. It was crucial to know whether the GP I111-ila complexes present in This suggests that a direct structural defect in the complexes may account for the lack of the aggregation response. As a precaution against the binding of 125I-fibrinogen to anti-fibrinogen antibodies trapped nonspecifically in the GP HIb-IIa precipitate, these experiments were performed using a rabbit anti-human platelet antibody preparation that had been passed through a fibrinogen-Sepharose 4B affinity column. As would be expected, incubation ofTriton X-100-soluble extracts of normal platelets with EDTA before the first dimension electrophoresis resulted in a loss in the fibrinogen-binding properties of the dissociated complex (not illustrated). This was unusual, because GP Ilb and GP i11a are normally solubilized from human platelets by nonionic detergent as the divalent cation-mediated heterodimer, and addition of EDTA (or EGTA) to the complexes in solution is required for dissociation of the individual glycoproteins (13, 14, 18, 30, (35) (36) (37) .
Addition of EDTA to intact normal platelets at room temperature has little or no effect (31, 36) , presumably because the divalent cations that mediate complex formation are inaccessible for chelation. One possible explanation for the low concentration of GP lIb-IIIa complexes in extracts of EDTA-washed C.M. platelets was that a structural defect prevented complex formation. This was excluded when it was found that C.M. platelets isolated in a calcium-containing buffer gave an abundant GP IIb-II~a immunoprecipitate when analyzed by CIE and bound quantitatively normal amounts of the GP HIb-HIla-dependent monoclonal antibodies. These findings also preclude the patient being considered heterozygous for classic thrombasthenia.
There is now overwhelming evidence that GP IIb-IIIa complexes are a prominent component of the surface membrane of circulating platelets. the complex in detergent extracts of unstimulated platelets by electrophoresis on nondenaturing, polyacrylamide gradient gels. These studies underline the results that have been obtained for normal platelets using CIE (6, 8, 13, 18, (30) (31) (32) . At room temperature, AP-2 binds similarly to normal platelets in the presence of divalent cations or with EDTA (16, 31) . However, the number of binding sites for T IO on normal platelets has been shown to fall to 50% of usual levels after divalent cation chelation with EDTA for 1 h at 220C (17) . In contrast, when these antibodies were incubated with C.M. platelets at room temperature, the number of binding sites fell to < 10% within 30 (44) , all point to GP IIb-IIa being the fibrinogen receptor on normal human platelets. Fibrinogen binding to ADP-stimulated C.M. platelets did not occur despite the ability ofGP IIb and GP IIIa to form complexes in these platelets. In normal human platelets the fibrinogen binding domain is exposed only after platelet activation. Thus, the defect in C.M. platelets may arise through either an abnormality in the mechanism of exposure of the fibrinogen-binding conformation on GP lIb-IIIa or be a result of a structural modification directly affecting the fibrinogen-binding determinant. Several studies have shown that a divalent cation-dependent interaction between fibrinogen and GP IlIb-IIIa may be demonstrated after isolation ofthe complex and that this occurs in the absence of ADP (32, 42, 44) . Such a finding implies that some, at least, ofthe isolated complexes directly express the fibrinogenbinding site. We studied the interaction between fibrinogen and GP IIb-IIIa complexes by incorporating I'1-fibrinogen into the intermediate gel during CIE. The GP Ib11ila complexes ofCa2+-washed C.M. platelets failed to bind fibrinogen, which strongly suggests the presence of a defect close to or influencing the fibrinogen-binding determinant on the complexes. Interestingly, as in type I thrombasthenia (see reference 3), the abnormality was associated with a severe decrease in the fibrinogen content of the a-granules of the platelets.
Thus, the patient C.M. appears to represent a new subgroup ofthrombasthenia where platelets contain unstable GP IIb-IIIa complexes unable to support fibrinogen binding. The abnormality may also extend to other adhesive proteins (3, 45) , for preliminary results also suggest a defective binding of von Willebrand factor to ADP-and thrombin-stimulated platelets (C. Mazurier and A. T. Nurden, unpublished results). The abnormalities present in the platelets ofthe patient are responsible for a lifelong bleeding disorder. No such problems have been experienced by other family members while an examination of the platelets of both parents has failed to reveal defects of GP Ilb-IIIa complex dissociation. It is possible therefore that the patient herself has been the subject ofa gene mutation. However, some prudence must be exercised in such an interpretation for it is possible that purported heterozygotes for this type ofvariant may be difficult to distinguish using present technology. Meanwhile, further studies on the GP IIb-IIa heterodimers ofpatients such as C.M. may help to define the functional site ofthis complex, which has a key role in the mechanism of platelet aggregation.
